Kiniksa plans Phase 2b trial of abiprubart in Sjogren's Disease; reports RA Cohort 4 data

Kiniksa Pharmaceuticals International, plc

Phase 2b trial in Sjogren's Disease to initiate 2H 2024; 201 patients, 24-week placebo-controlled, primary endpoint ESSDAI.
Cohort 4 RA data: abiprubart 400 mg SC monthly showed DAS28-CRP LS mean difference -0.58 vs placebo (p=0.109, not significant).
Statistically significant ~40% reduction in Rheumatoid Factor in Cohort 4 (p=0.0003); pooled analysis DAS28-CRP diff -0.52 (nominal p=0.010).
Abiprubart development in Sjogren's fully funded through Phase 3; company expects to remain cash flow positive annually.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.